

CURRICULUM VITAE
John West Day, MD, PhD
November 10, 2016

BUSINESS ADDRESS

Department of Neurology
Division of Neuromuscular Medicine
Stanford Neuroscience Health Center
213 Quarry Road
M/C 5979
Palo Alto, CA 94304

EDUCATION

1969 – 1973 BA, Physics, Oberlin College, Oberlin, Ohio
1974 – 1977 M.D., Medicine, University of Minnesota, Minneapolis, Minnesota
1977 – 1982 Ph.D., Neuroscience, Albert Einstein College of Medicine, Bronx, New York
M.V.L. Bennett, Thesis Advisor

POSTDOCTORAL TRAINING

1982 – 1983 Montefiore Hospital, Bronx, New York, Internship in Internal Medicine
1983 – 1986 University of California, San Francisco, Resident in Neurology
1985 – 1986 Chief Resident of Neurology, Robert A. Fishman, Department Chairman
1986 – 1987 University of California, San Francisco, California
Clinical Neurophysiology/Electromyography, Richard Olney, Fellowship Director

ACADEMIC APPOINTMENTS

1986 – 1991 Department of Neurology, University of California, San Francisco, Assistant Professor
1992 – 1997 Department of Neurology, University of Minnesota, Assistant Professor
1996 – 2011 Graduate Program in Neuroscience, University of Minnesota, Full Member
1997 – 2001 Department of Neurology, University of Minnesota, Associate Professor
2002 – 2011 Department of Neurology, University of Minnesota, Professor
2006 – 2011 Department of Pediatrics, University of Minnesota, Professor
2008 – 2011 Department of Genetics, Cell Biology, Development, University Of Minnesota, Professor
2011 current Department of Neurology, University of Minnesota, Adjunct Professor
2011 current Prof Neurology, Pediatrics, Pathology, Stanford University, Dir. Neuromuscular Division

ACADEMIC ADMINISTRATIVE APPOINTMENTS

1996 – 2003 Director, Center for Muscle Disorders, University of Minnesota
1997 – 2003 Medical Director, Clinical Neuroscience Research Unit
1999 – 2001 Associate Head for Clinical Affairs, Neurology Department, U of MN
1999 – 2011 Institute of Human Genetics, Executive Board, University of Minnesota
2003 – 2011 Director, Paul and Sheila Wellstone Muscular Dystrophy Center, U of MN
2011 – Director, Neuromuscular Division and Clinics, Stanford University

CLINICAL/HOSPITAL APPOINTMENTS

1994 – 2011 Director, Muscular Dystrophy Clinic, University of Minnesota
1996 – 1999 Director of Clinical Electrophysiology Laboratories, University of Minnesota
1997 – 2011 Medical Director, Neuromuscular Histology Laboratory
1999 – 2011 Medical Director, Muscular Dystrophy and ALS Clinic, University of Minnesota
1999 – 2003 Medical Director, University of Minnesota Ataxia Clinic

1999 – 2001 Chief of Service, Neurology Service, Fairview University Medical Center
 2005 – 2011 Director, Neuromuscular Clinic, Gillette Children's Specialty Care
 2011 – Medical Director, Neuromuscular Clinics, Stanford University

CONSULTING AND ADVISORY POSITIONS

1996 – 2011 Myasthenia Gravis Foundation, Minnesota Chapter, Medical Advisory Board
 1998 – 2001 Muscular Dystrophy Association, Minnesota Chapter, Board Member
 2002 – 2008 National Ataxia Association, Board Member
 2004 – 2008 National Ataxia Association, Clinic-Research Liaison
 2004 – 2010 Muscular Dystrophy Association, Medical Advisory Committee
 2005 Muscular Dystrophy Advisory Committee, NIH/NINDS/NIAMS
 2005 – 2007 PTC Therapeutics, Chairman PTC124 Data Management Review Committee
 2005 – present United Council for Neurological Subspecialties, Neuromuscular Path Adv Committee
 2006 – 2008 Asklepios Biotherapeutics, Duchenne Gene Therapy Advisory Committee
 2006 – present Myotonic Dystrophy Foundation, National Advisory Committee
 2008 – present NIH-CINCH, Chairman Data and Safety Management Board
 2008 – present NIH Genetics of Health and Disease (GHD) Study Section Member
 2009 NIH/NIAMS Advisory Committee on Muscular Dystrophy Research
 2009-2011 Chair, NIH DSMB, CINCH cooperative mexilitene trial for non-dystrophic myotonia
 2010-present Amer Acad of Neurology, Guidelines Committee for myotonic dystrophy treatment
 2011-present Chair, NIH DSMB, International trial of prednisone for Duchenne muscular dystrophy
 2013 -2014 Chair, MDA National Clinic Directors' Meeting

SCIENTIFIC ADMINISTRATIVE AND ORGANIZATIONAL ACTIVITIES

Journal Referee: Annals of Neurology, Brain Research, Muscle and Nerve, Neurology, Pediatric Neurology, Journal of Neurology, Neurosurgery and Psychiatry, Journal Neuroscience, Human Molecular Genetics, American Journal Human Genetics
 1994-1996 Abstract Reviewer, American Academy of Neurology Annual Meeting
 1994-1995 Chair: Pathogenesis of ALS, American Academy of Neurology
 1996 Course Director: American Association of Electrodiagnostic Medicine
 2004-present Scientific Advisory Committee, National Registry for DM and FSHD
 2005 Section Co-Chairman, NIH Burden of Muscle Disease Workshop, Washington, D.C.
 2005 Organizer, Director, First International Ataxia Investigators' Meeting, Tampa, FL
 2008 Ad Hoc Member, NIH Genetics of Health and Disease Study Section
 2008 Organizer, Director, 2nd International Ataxia Investigators' Meeting, Las Vegas, NV
 2014 Chair, Muscular Dystrophy Association Annual Meeting, Chicago, IL

GRANT SUPPORT

Source	Period	Appox Total	Title
NIH	7/78-6/81	37,468	Iontophoretic Study of Hatchedfish Giant Synapse
NIH	7/86-6/89	189,400	Molecular Basis of Opiate Receptor Physiology
Epilepsy Foundation	7/89-6/90	25,000	Cellular Physiol of Epilepsy-Permissive Neurons
Univ. MN Grad. School	7/95-6/96	20,000	Characterization of a Form of Myotonic Dystrophy
U MN Grad Sch, Dir.	7/96-6/98	20,000	Interdisciplinary Center for Muscle Disease
NIH, Co-Inv.	7/97-6/00	500,000	Genetic Mapping of a Novel Disease
NIH, Co-I	6/1/97-5/31/00	200,000	Cloning and characterizing a second DM locus
Centeon Pharm., PI	12/96-11/99	15,000	Effects of Immunoglobulin on Myasthenia Gravis
FDA Orphan Drug, PI	10/1/97-9/30/00	75,000	Effects of Immunoglobulin on Myasthenia Gravis
MDA, Co-PI	1/1/98-12/32/00	20,000	Effects of Immunoglobulin on Myasthenia Gravis
U MN Grd Sch, Dir.	7/98-6/01	100,000	Interdisciplinary Center for Muscle Disease, Direct
MDA, Co-PI	12/98-11/01	200,000	Genetic and Clinical Characterization of DM2

NAF, Co-Inv	1/1/00-12/31/00	20,000	Murine model untranslated CTG repeats in SCA8
NAF, PI	1/1/00-12/31/00	20,000	Clinical and Genetic Characterization of SCA5
MMF, PI	4/1/00-9/30/01	12,000	MRI Brain Imaging in SCA8
NIH, Co-PI	4/1/00-5/31/12	1,000,000	Muscle Training Grant
NIH, Co-I	6/1/00-5/31/05	1,000,000	Genetic mapping of novel DM locus
NIH, Co-I	6/1/00-5/31/05	1,125,000	Molecular and Genetic Characterization of SCA8
ALS Assoc, PI	9/1/01-8/31/02	60,000	Genetic mapping of a novel form of ALS
ALS Assoc, PI	1/1/03-12/31/03	60,000	Genetic mapping of a novel form of ALS
MMF, PI	3/1/2003-2/29/2004	12,000	MRI and genetic characterization of SCA5
AHC, Co-PI	4/14/04-4/13/07	250,000	Novel genetic analyses of neuromuscular disorders
NASH Fund, PI	3/1/04-6/30/05	40,000	Development of Clinical Testing Program for DMD
MMF, PI	3/1/04-2/28/05	40,000	Clinical trials in Duchenne muscular dystrophy
DOD, PI	1/1/2005-12/31/06	500,000	Cord Blood Transplantation into Skeletal Muscle
NASH Fund, PI	3/1/04-6/30/05	50,000	Development of Metabolic Support for DMD
NIH, Co-I	6/1/05-5/31/09	1,000,000	Transgenic Model of DM2
NIH, Co-I	4/1/06-3/31/11	1,250,000	Clinical and Molecular Characterization of SCA8
NASH Found, Co-I	1/1/2007-1/1/2009	750,000	TAT-Utrophin treatment of DMD
NIH, R01 PI	4/1/07-3/31/12	1,250,000	CNS Involvement in DM1 and DM2
Insmmed, Site PI	3/1/2008-2/28//2009	100,000	IPLEX treatment of DM1
PTC, Site PI	3/1/2009-2/28/2009	300,000	PTC124 treatment of DMD point mutations
Genzyme, Site PI	2/1/2008-1/31/2007	50,000	Myozyme treatment of adult-onset Pompe
NIH, P01 Proj PI	4/1/08-3/31/13	1,250,000	CNS Involvement in Childhood DM1
NIH, PI (R13)	4/1/2008	40,000	International Ataxia Investigators' Meeting
NASH Found, PI	10/1/2007-9/30/2012	1,000,000	Cell-based treatment of DMD
MDA, PI	8/1/2008-7/31/2011	300,000	DMD Clinical Research Network
NIH P30, PI	6/1/2009-5/31/2014	2,000,000	MDCenter Core Laboratories
NIH, R01 Co-I	1/2007-12/2011	60,000	Dystrophin phenotype-genotype correlations
NIH , RC2 Co-I	9/2009-9/2011	30,000	Facioscapulohumeral dystrophy iPSCs
MDA, Site PI	6/2009-5/2012	25,000	Outcome measures in infants with Duchenne
MDA, Site PI	6/2009-5/2012	25,000	Duchenne cardiomyopathy natural history
PTC, Site PI	3/2008-2/2012	25,000	Open-label nonsense-mediated dystrophin study
PTC, Site PI	3/2013-2/2015	25,000	Open-label nonsense-mediated dystrophin study
Genzyme, PI	20/2011-12/2014	30,000	Enzyme replacement in infantile-onset Pompe
Isis, PI	5/2012-12/2014	500,000	Phase 2, CS3A, Antisense for SMA1 infants
Chld Hlth Rsch Init	9/2012-8/2014	200,000	Imaging and Cognitive Function in DM1 children
Marigold Foundation	6/2011-5/2013	20,000	Executive function outcome measures for DM
NIH, P01 Proj PI	10/1/13-9/30/18	2,000,000	CNS Involvement in Childhood DM1
NIH, MDA	10/1/13-9/30/16	300,000	Myotonic Dystrophy Clinical Research Network
Marigold Foundation	1/1/13-1/1/15	10,000	Fatigue in Myotonic Dystrophy
Marigold Foundation	1/1/13-1/1/17	250,000	CNS and Sleep aspects of Myotonic Dystrophy
Ariel Bardin	1/1/13-1/1/15	200,000	CNS changes in Myotonic Dystrophy Childhood
Isis, PI	7/1/14-7/31/16	600,000	Phase 3, CS3A, Antisense for SMA1 infants
Isis, PI	11/15/14-11/15/16	1,500,000	Phase 3, CS4, Antisense for SMA2 children
Jain Foundation	11/1/14-10/31/17	150,000	Natural history of LGMD-2B
Isis, PI	1/1/15-12/31/17	500,000	Phase 2, CS2, Antisense treatment of DM1
PNMRC, SMA Found	1/1/15-12/31/16	450,000	Pediatric Neuromuscular Research Center
NIH/MDA	5/1/13-4/30/16	45,000	Natural History and Genetic Modifiers of CMT
Sarepta Pharm	11/1/2014-12/1/2015	300,000	Phase 3, Antisense for Exon 51 Skippable DMD
Valerion Pharm	1/1/2015-12/31/2016	40,000	Natural History of Myotubular Myopathy
Audentes Pharm	1/1/2015-12/31/2016	30,000	Phase 0 and Phase 2 of AAV gene Rx for MTM

CERTIFICATION AND LICENSURE

1984-1994 Medical license, California

3/30/1988 Diplomat, American Board of Psychiatry and Neurology - Certificate 30137 (indefinitely)
 1989 Diplomat, American Board of Electrodiagnostic Medicine - Certificate 543
 1992-present Medical license, Minnesota, 35127
 1996 Diplomat, American Board of Psych & Neurol, special qualifications Clin Neurophysiol
 1999 Diplomat, American Academy of Neurology, Qualification in Neuromuscular Pathology
 2011 ACGME Neuromuscular Medicine Certification Exam
 2011-present Medical license, California, G52734

MILITARY SERVICE: None

HONORS AND AWARDS

1978 Grass Foundation Fellow in Neurophysiology, Marine Biological Lab, Woods Holes, MA
 1978-1981 NIH/NRSA Postdoctoral Fellowship
 1985 Alpha Omega Alpha
 1985 Distinguished Teaching Award, University of California San Francisco
 1986 Clinical Investigator Development Award, NINCDS, NIH
 1996 Distinguished Teaching Award, University of Minnesota Medical School
 1996-present Recognized by Best Doctors in America
 2001 Distinguished Teaching Award, University of Minnesota Medical School
 2002 Leon Poliachik Humanitarian Award, University of Minnesota ALS Clinic
 2003 Distinguished Teaching Award, University of Minnesota Medical School
 2005 Outstanding Teaching Award, University of Minnesota Medical School
 2005 Distinguished Teaching Award, University of Minnesota Medical School
 2007 All University Post-Baccalaureate Teaching Award, University of Minnesota
 2007 Lifetime Member Academy of Distinguished Teachers, University of Minnesota
 2010 Recognized among Best Physicians in Minnesota, Twin Cities Magazine
 2014 Excellence in Clinical Care, National Myotonic Dystrophy Meeting, Washington, DC

MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES

1978-present Society for Neuroscience
 1978-present American Association for the Advancement of Science
 1984-present American Academy of Neurology
 1989-present American Association of Electrodiagnostic Medicine
 2001-present American Association of Human Genetics
 2001-present World Muscle Society
 2006-present American Neurological Association, Fellow

TEACHING AND MENTORING ACTIVITIES

STUDENT TEACHING:

1986, "Outpatient Neurology," Fourth Year Medical Students, University of California, San Francisco
 1987-1991 "Introduction to Clinical Medicine/Neurology," Second Year Medical Students, UCSF
 1988-1991 "Stroke," Physical Therapy Students, University of California, San Francisco,
 1990-1991 "Headache and Pain," Clinical Pharmacology, Fourth Year Medical Students, UCSF
 1991 "The Neurological Exam," 2nd Year Medical Students, UCSF
 1992-present "Neuromuscular Disease," Second Year Medical Students, University of Minnesota
 1993-2001 "Clinical Correlations - Myasthenia Gravis," First Year Medical Students, U of MN
 1993-1996 "Coma" Internal Medicine Clerkship, University of Minnesota, twice yearly
 1993-present "Pain and Pain Management" Second Year Medical Students, University of Minnesota
 1993-present "Headache and Subarachnoid Hemorrhage" Second Year Medical Students, U of MN
 1995 "Congenital myasthenia" Neuroscience Students Itasca Summer Program, U of MN

- 1992-1999 “Disorders of neuromuscular transmission” Neuroscience Grad Stud, U of MN
- 1992-1999 Site Coordinator, Neurology Clerkship University of Minnesota: Organize schedule and orient students for each 4 week rotation. Discuss expectations with faculty and help them plan tutorial sessions. Help organize and motivate house staff to participate in teaching. Grade exams and evaluate students each rotation.
- 1996-1999 Neurology Clerkship Director for all participating hospitals, University of Minnesota
- 1998-present Nervous System and Muscle Disease, Pathophysiology Course Director, principle 2nd Year Medical Student Clinical Neuroscience Course, U of MN
- 1996-1999 Director, “Introduction to Neuromuscular Junction”, a 1-week laboratory course, Neuroscience Students Itasca Summer Program, University of Minnesota,
- 1997-present “Introduction to Neurology”, OT/PT students, University of Minnesota,
- 1999 “A Clinical Approach to Pain” Human Behavior Course 1st Year Med Students U of MN
- 2000-2001 “The myotonic dystrophies”, Biology 3700, University of Minnesota
- 2000-present “Introduction to muscle disorders”, Biochemistry 5444 University of Minnesota
- 2000-present “Normal neuromuscular transmission”, Biochemistry 5444 University of Minnesota
- 2000-present “Disorders of sarcolemmal ion channels”, Biochemistry 5444 University of Minnesota
- 2000-present “Muscular dystrophies”, Biochemistry 5444 University of Minnesota
- 2006-2010 “Introduction to Cranial Nerves”, year 1 medical student Neurosci Course, University MN
- 2011 “Genetic bases of muscular dystrophies”, Biology 3700, University of Minnesota

RESIDENT AND FELLOWSHIP TEACHING:

- 1985-1991 Neurology Resident Neuroscience Course in Neurophysiology, UCSF
- 1992 “Neurological Emergencies-Headache” Neurology Residents, U of MN
- 1992 “Neurological Emergencies-Acute Weakness” Neurology Residents, U of MN
- 1992-1995 “Introduction to Electromyography”, Neurology Resident 4 lectures, 4 times/yr, U of MN
- 1993 “Diseases of Muscle”, Neurology Resident Neurosci, Symp Organizer/Lecturer, U of MN
- 1993-2004, “Introduction to Electromyography”, PM&R Resident, U of MN
- 1993-1996 “Myasthenia Gravis”, Ophthalmology Resident Education Series, U of MN
- 1994, 2002, 2004 “Metabolic Encephalomyopathies”, Neurology Resident Neuroscience Series U of MN
- 1994 “Neuromuscular Junction”, Neurol Resident Neurosci Symp Organizer/Lecturer, U of MN
- 1994-present “The Neurological Exam”, Neurology Resident Neuroscience Series, U of MN
- 1999, 2004 “Myopathies”, Neurology Resident Neuroscience Series, U of MN (4 lectures)
- 1995, 1996, 1997 Intro to Neuromuscular Disorders, Medicine Resident Education, U of MN
- 1994, 1996, 1997 “Myopathies”, PM&R Resident Education Series, U of MN
- 1996, 1997 “Neuromuscular Junction Abnormalities”, PM&R Resident Education Series U of MN
- 1996-present “Introduction to Electromyography”, Neurosurgery Resident Education Series, U of MN
- 2005-present “Basic Neurophysiology”, Neurol Resident Neurosci Symp Organizer/Lecturer, U of MN
- 2012 “Clinic Neurophysiology of NMJ Disorders”, Stanford Neurology Residents Didactic Series
- 2013 “Introduction to Pediatric Neuromuscular Disease”, Stanford Neurology Residents Didactic Series

FELLOWSHIP TEACHING:

- 1986-1991 Neuromuscular Fellowship, Participating Faculty, UCSF
- 1991-2011 Neuromuscular Fellowship, Participating Faculty, U of MN
- 1996-2002 ACGME Neuromuscular/Clinical Neurophysiology Fellowship, Director, U of MN
- 2008-2010 Muscular Dystrophy Clinical/Research Fellowship, Director, U of MN
- 2012-present Stanford ACGME Neuromuscular Fellowship, Director
- 2012-present Stanford Weekly Neuromuscular CME Case Conference, Director
- 2013 Stanford Neuromuscular Fellowship Weekly Didactic Series, Director & frequent Lecturer

TEACHING CONFERENCES:

- 1985 “Thunderclap Headache - An Unruptured Cerebral Aneurysm” Neurology Grand Rounds, UCSF
 1986 “Normocalcemic Tetany” Neurology Grand Rounds, UCSF
 1989 “Electrophysiological Characterization of Spasticity” Neurology Grand Rounds, UCSF
 1990 “Ectopic Impulse Generation and Ephaptic Transmission in Neuropathies” Neuro Grd Rds, UCSF
 1991 “Adenosine Modulation of Transmission at the Neuromuscular Junction” Neuro Grd Rds, UCSF
 1992 “Hypokalemic Periodic Paralysis” Clinical Neurosciences Conference, U of MN
 1993 “Multifocal Demyelinating Neuropathies”, Neuromuscular Conference, U of MN
 1993 “Radiation Amyotrophy”, Neuromuscular Conference, U of MN
 1994 “Periodic Paralysis - Quantitative Assessment”, Neuromuscular Conference, U of MN
 1994 “Mitochondrial Myopathies – Clinical/Basic Correlations” Clinical Neurosciences Conf, U of MN
 1995 “Temporal Aspects of Conduction Block”, Clinical Neurosciences Conf, U of MN
 1997 “Paraneoplastic Disorders”, Clinical Neurosciences Conference, U of MN
 2000 “Spinocerebellar Ataxia type 8”, Clinical Neurosciences Conference, U of MN
 2001 “Myotonic Dystrophy type 2”, Clinical Neurosciences Conference, U of MN
 2001 “Myotonic Dystrophy type 2”, Department of Neuroscience Colloquium, U of MN
 2002 “Myotonic Dystrophy type 2”, Dept of Gen, Cell Biol, Dev. Seminar Series, U of MN
 2003 “Myotonic Dystrophy type 2”, Department of Neurology Seminar Series, U of MN
 2004 “Myotonic Dystrophy type 2”, Department of Psychiatry Seminar Series, U of MN
 2005 “The Myotonic Dystrophies”, Department of Internal Medicine Grand Rounds, U of MN
 2005 “Developmental Defects in Myotonic Dystrophy”, Dept. of Pediatrics Grand Rounds, U of MN
 2004 “Novel degenerative disease: FSHD”, Department of Neurology Seminar Series, U of MN
 2005 “Duchenne Muscular Dystrophy Treatment”, Department of Neurology Seminar Series, U of MN
 2006 “Myotonic Dystrophy and the Central Nervous System”, Clinical Neurosciences, U of MN
 2008 “Management of Muscular Dystrophy Patients”, Gillette Healthcare Neuroscience Conference
 2010 “Congenital Muscular Dystrophies”, Gillette Healthcare Neuroscience Conference
 2011 “Genetics of Muscular Dystrophy”, Human Genetics Course, U of MN
 2011 Congenital Muscle Disorders Workshop, Stanford Neuromuscular Program
 2013 International Update on Nemaline Myopathy, Stanford Neuromuscular Program
 2014 Myotonic Dystrophy Patient Informational Meeting, Stanford Neuromuscular Program
 2014 CMT Awareness Conference, Stanford Neuromuscular Program
 2015 California Myotonic Dystrophy Patient Meeting, Stanford Neuromuscular Program and UC Irvine
 2016 California Myotonic Dystrophy Patient Meeting, Stanford Neuromuscular Program and UC Davis

MEDICAL STUDENTS:***Medical Student Advisees:***

- 1992: Thanh Dang
 1999: William Malcolm, Melissa Mark
 2000: L.T. Nguyen
 2002: Joshua Ramsmeier
 2004: Kristina E Catrine, Brian A Hunter, Amanda J Morehouse, Derek Johnson,
 2005: Sarah Powel
 2006: Manish C. Champaneria, Catherine Ehlen, Jonathan Faust, Brooke Glessing, Barton Iverson, Mollie Johnston, Justine Pidcock, Adrienne E. Soucy, Adam Todd

2007: Thuy An Hoang, Danah M Holman, Matthew W Miller, Sara A Rademacher, Laura C. Speltz, Christopher M Walker

2009: Elisabeth Hurliman, John Cunningham, Nancy Henry-Socha, Yi-Lo Yu, Stephanie Aamodt, Maureen Handoko, Angela Hewitt, Cristina Albott

2010 Mohammad Gol, Roy Bryan Jr., Jose Mejia, Yun Lin

GRADUATE STUDENTS & POSTDOCS:

Graduate Students:

1995-1999 Jon Falkenberg (with Iaizzo, Physiology)
 1999-2003 Christina Liquori (with Ranum, MCDBG)
 2002-2005 Anne Mosemiller (with Ranum, Neuroscience)
 2003-2007 Jamie Malikowski (with Ranum, MCDBG)
 2003-2007 Randy Daughters (with Ranum, MCDBG)
 2005-2007 Karen Armbrust (with Ranum, Neuroscience)

Postdoctoral Trainees:

1993-1995 Bula Bhattacharyya, (with Gomez)
 1998-1999 Mark Leppert (with Ranum)
 1998-2001 Melinda Moseley (with Ranum)
 2002-2005 Yoshio Ikeda (with Ranum)
 2006-2008 Peter Karachunski (MDA Training Fellowship)

PhD Thesis Committees:

1998 Tara Ward, Veterinary School Pathobiology
 1998 Jack Grinband, Neuroscience and Biochemistry
 1999 Ben Rosner, Mechanical Engineering
 1999 Jon Falkenberg, Physiology
 1999 Jack Surek, Biochemistry
 2001 Matthew Hagen, Neuroscience
 2007 Chiao-Nan Chen, Physical Therapy
 2007 Eric Richardson, Biomedical Engineering
 2007 Justin Barnes, Neuroscience
 2008 Daniel Franc, Neuroscience
 2010 Blake Edwards, Neuroscience
 2011 Justin Barnes, Neuroscience
 2011 Yun Lin, Neuroscience

EXTRAMURAL INVITED PRESENTATIONS

1985, 1986 "Introduction to Neurology" Lecture series for Nurse Practitioners, UCSF
 1986 "Acute Management of Cerebral Infarct," Symposium Organizer, UCSF
 1987 "Clinical Electrophysiology," Dept. of Orthopedics, UCSF
 1990 "Advances in Pain and Pain Management," Amer Col Phys Ann Mtg, SF, CA
 1991 "Normocalcemic Tetany," Neurology Grand Rounds, University of Texas, Houston
 1991 "Inherited Neuronal Hyperexcitability," Neurology Grand Rounds, University of Utah
 1991 "Adenosine Modulation of Muscle Acetylcholine Receptors," Department of Neurology, U of MN
 1993 "Advances in Pre-Synaptic Physiology," Amer Assoc Clin Neurophy Ann Mtg, UCSF
 1994 "Temporal Aspects of Conduction Block," Amer Assoc Electrodiag Med Ann Mtg, San Francisco
 1994-2004 "Clinical Features of Myasthenia Gravis", MG Foundation, MN Chapter Ann Mtg (6 talks)
 1995 "An Update on Ocular Myasthenia Gravis", MG Foundation, MN Chapter Ann Mtg
 1996, "Immunosuppressive Treatment of Inflammatory Neuropathies", Neurology Grand Rounds, U NB
 1997 "PROMM, Similarities with Myotonic Dystrophy" Grand Rounds, Stanford Medical School

- 1997 “Immunosuppressive Treatment of Inflammatory Neuropathies”, Spec Lecture, Stanford Med Sch
- 1997 “A Novel form of Myotonic Dystrophy in a Minnesota Family”, ENMC, Netherlands
- 1998 “Clinical features of Myotonic Dystrophy type 2”, IX Internatl Conf on Neuromus Dis, Adelaide
- 1998 “A Novel form of Myotonic Dystrophy”, Grand Rounds, OHSU, Portland
- 1999 “The DM2 locus in PROMM”, 2nd Intl Myotonic Dystrophy Consortium, North Carolina
- 2000 “Clinical Features of DM2”, European Neuromuscular Consortium (ENMC), Netherlands
- 2000 “Clinical and Genetic Features of DM2”, 3rd Intl Myotonic Dystrophy Consortium, Kyoto
- 2001 “Clinical and Genetic Features of DM2”, Special Invited Lecture, Wurzburg, Germany
- 2002 “The Myotonic Dystrophies, International Neuromuscular Congress”, Vancouver
- 2002 “Recent Advances in Myotonic Dystrophies, University Virginia, Charlottesville
- 2003 “Clinical and Molecular Features of DM2”, European Neuromuscular Consortium, Netherlands
- 2003 “Clinical and Molecular Features of DM2”, 4th Intl Myotonic Dystrophy Consortium, Glasgow
- 2003 “Stem Cells in Muscular Dystrophy”, Parents Project for Muscular Dystrophy, Cincinnati
- 2003 “RNA toxicity in the Myotonic Dystrophies”, UCLA Neurology Grand Rounds, Los Angeles, CA
- 2003 “RNA toxicity in the Myotonic Dystrophies”, Mayo Neurology Grand Rounds, Rochester, MN
- 2004 “RNA toxicity of the Myotonic Dystrophies,” U IA Neurology Grand Rounds, Iowa City, IA
- 2004 “Pathophysiology of the Myotonic Dystrophies”, World Muscle Soc Keynote, Goteborg, Sweden
- 2006 “RNA Mediated Neuromuscular Disease”, Int’l Neuromuscular Congress Keynote, Istanbul
- 2006 “Clinical Features of Myotonic Dystrophy”, Int’l Neuromuscular Congress Symposium, Istanbul
- 2007 “Clinical Features of Myotonic Dystrophy”, Neurology Grand Rounds, Mass Gen Hosp, Boston
- 2008 “Genetics of ALS”, ACNS Annual Meeting, Savannah, Georgia
- 2008 “Myotonic Dystrophy: Unusual Mechanisms underlie a Complex Phenotype”, Neurology Grand Rounds, Stanford University, Palo Alto
- 2008 “RNA Pathogenesis of Myotonic Dystrophy”, Department of Genetics, UCSD, San Diego, CA
- 2009 “CNS Aspects of Myotonic Dystrophy”, Keynote Address, International Myotonic Dystrophy Consortium, Wurzburg, Germany
- 2010 “Neuromuscular Disorders Come Into Focus: Impending Treatments for Muscular Dystrophy”, Keynote Address, Annual Stanford University Neuroscience Conference, SF, CA
- 2011 “Central Nervous System Effects of Myotonic Dystrophy”, Keynote Address, International Myotonic Dystrophy Consortium, Clearwater, FL
- 2011 “How far to go in diagnosing neuromuscular disorders: relevance of genetic testing for sporadic and familial disease”. Annual Stanford University Neuroscience Conference, SF, CA
- 2012 “Congenital Muscle Disease Clinico-Pathological Correlations”, Regional Workshop, Director and Participant, Stanford, CA
- 2013 “Novel approaches to Diagnosis and Treatment of Neuromuscular Disease”, MDA Patient Conference, Portland, OR
- 2013 “Understanding the CNS in Myotonic Dystrophy”, MDA Patient Conference, Portland, OR
- 2013 “Central Nervous System Involvement in Myotonic Dystrophy”, Marigold Workshop, Milan, Italy
- 2013 “Developing a Repository of Patient-Derived Specimens in Myotonic Dystrophy”, Marigold Workshop, Milan, Italy
- 2013 “Genetic Modification in Neuromuscular Disease”, MDA Patient Conference, Concord, CA
- 2013 “Neuromuscular Case Presentations and Take Home Messages”. Annual Stanford University Neuroscience Conference, SF, CA
- 2013 “Nemaline Myopathy International Conference”, Director and Participant, Stanford, CA

- 2014 “Update on Genetics in Neuromuscular Disease”, Presenter, and overall meeting Chairman, National Muscular Dystrophy Association Clinic Directors’ Meeting, Chicago
- 2014 “Advances in Neuromuscular Genetics and Treatment”, Muscular Dystrophy Association Directors’ and Sponsors’ Meeting, Los Angeles
- 2014 “Outcome measures in DMD”, Chairman, PTC Therapeutics, NJ
- 2014 “Acute Neuromuscular Disorders”, American Academy of Pediatrics, San Diego
- 2014 “Antisense Treatment of Neuromuscular Disorders”, University of California, Davis
- 2014 “Update on Diagnosis and Management of Genetic Neuromuscular Disorder”, Annual Stanford Clinical Neuroscience Conference, SF, CA
- 2014 “Clinical Aspects of CNS Changes in Myotonic Dystrophy”, Univ Florida, Gainesville
- 2015 “New Methods for Neuromuscular Disorder Treatment”, Barrows Institute, Phoenix, AZ

PUBLICATIONS

1. Aljure E, **Day JW**, Bennett MVL. Postsynaptic depression of Mauthner cell-mediated startle reflex, a possible contributor to habituation. *Brain Res* (1980) 188:261-268.
2. **Day JW**, Hall DH, Hall LM, Bennett MVL. Alpha-bungarotoxin labeling and acetyl-cholinesterase localization at the Mauthner fiber giant synapse in the hatchetfish. *J Neuroscience* (1983) 3:272-279.
3. **Day JW**, Huse WD, Bennett MVL. Time course of miniature postsynaptic potentials at the Mauthner fiber giant synapse of the hatchetfish. *Brain Res* (1985) 325:115-128.
4. Huse WD, **Day JW**, Bennett MVL. Postsynaptic currents at the Mauthner fiber giant synapse of the hatchetfish. *Brain Res* (1985) 325:129-141.
5. **Day JW**, Raskin NH, Thunderclap headache: symptom of unruptured cerebral aneurysm. *The Lancet* (November 29, 1986) 1247-1248.
6. Adams M, Rhyner P, **Day JW**, DeArmond S, Smuckler EA. Whipple's disease confined to the central nervous system. *Ann Neurol* (1987) 21(1):104-108.
7. **Day JW**, Parry GJ. Normocalcemic tetany abolished by calcium infusion. *Ann Neurol* (1990) 27(4):438-440.
8. Pitchford S, **Day JW**, Gordon A, Mochly-Rosen D. Nicotinic acetylcholine receptor desensitization is regulated by activation-induced extracellular adenosine accumulation. *J Neurosci* (1992) 12(11):4540-4544.
9. Gomez CM, Bhattacharyya B, Charnet P, **Day JW**, Labarca C, Wollman RW, Lambert EH. A transgenic mouse model of the slow-channel syndrome. *Muscle Nerve* (1996) 19:79-87.
10. Brass TJ, Loushin MKH, **Day JW**, Iaizzo PA. An improved method for muscle force assessment in neuromuscular disease. *J Med Engineering and Technology* (1996) 20(2): 67-74.
11. Gomez CM, Maselli R, Gundeck JE, Chao M, **Day JW**, Tamamizu S, Lasalde JA, McNamee M, Wollman RL. Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction. *J Neurosci* (1997) 17(11):4170-4179.
12. Bhattacharyya BJ, Gomez CM, **Day JW**, Gundeck JE, Leonard S, Wollmann RL. Desensitization of mutant acetylcholine receptors in transgenic mice reduces the amplitude of neuromuscular synaptic currents. *Synapse* (1997) 27(4):367-77.

13. Gomez CM, Maselli R, Williams JM, Bhattacharyya BB, Wollmann RL, **Day JW**. Genetic manipulation of AChR responses suggests multiple causes of weakness in slow-channel syndrome. *Annals of the New York Academy of Sciences* (1998) 841:167-80.
14. Koob MD, **Day JW**, Benzow KA, Bird TD, Moseley ML, Ranum LPW. Rapid cloning of expanded trinucleotide repeat sequences from genomic DNA. *Nature Genetics* (1998) 18(1):72-5.
15. Wick MJ, Matthias-Hagen VL, **Day JW**, Gomez CM, McGlennen RC. Long range PCR-based diagnosis of Friedreich ataxia in the clinical molecular diagnosis laboratory. *Molecular Diagnosis* (1998) 3:3-9.
16. Ranum LPW. Rasmussen PF. Benzow KA. Koob MD. **Day JW**. Genetic mapping of a second myotonic dystrophy locus. *Nature Genetics* (1998) 19(2):196-8.
17. **Day JW**, Roellofs R, Leroy B, Pech I, Amos J, Benzow K, Ranum L. Clinical and genetic characteristics of a five generation family with a novel form of myotonic dystrophy. *Neuromuscular Disorders* (1999) (1):19-27.
18. Koob MD, Moseley M, Schut L, Bird T, Benzow KA, **Day JW**, Ranum LP. Identification of an untranslated CTG expansion in SCA8. *Nature Genetics* (1999) 21(4):379-84.
19. Li LY, Kelkar P, Exconde RE, **Day JW**, Parry GJ. Adult-onset "infant" botulism: an unusual cause of weakness in the intensive care unit. *Neurology* (1999) 53(4):891.
20. International Myotonic Dystrophy Consortium. New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC). *Neurology* (2000) 54(6):1218-21.
21. **Day JW**, Schut LJ, , Moseley ML, Ranum LPW. Spinocerebellar ataxia type 8 (SCA8) Clinical features of a large family. *Neurology* (2000) 55:649-657.
22. Koenigbauer, UF, Eastland T, **Day JW**. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. *Transfusion* (2000) 40:1203-1206.
23. Moseley ML, Schut LJ, Bird TD, Koob MD, **Day JW**, Ranum LP. SCA8 CTG repeat: en masse contractions in sperm and intergenerational sequence changes may play a role in reduced penetrance. *Human Molecular Genetics* (2000) 9(14):2125-30.
24. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, **Day JW***, Ranum LPW*. Myotonic Dystrophy Type 2: Caused by a CCTG Expansion in Intron 1 of *ZNF9*. *Science* (2001) 293:864-867.
25. **Day JW**, Sakamoto C, Lehmann-Horn, Iaizzo PA. Force assessment in periodic paralysis after electrical muscle stimulation. *Mayo Clinic Proceedings* (2002) 77(3):232-40.
26. Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, **Day JW**, Thornton CA, Nations SP, Bryan WW, Amato AA, Freimer ML, Parry GJ, Mendell JR. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. *Muscle and Nerve* (2002) 26:549-552.
27. Koc ON, **Day JW**, Nieder M, Gerson SL, Lazarus HM, Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome. *Bone Marrow Transplantation* (2002) 30:215-222.

28. **Day JW**, Ricker K, Jacobsen J, Rasmussen L, Dick K, Kress W, Schneider C, Koch M, Beilman G, Harrison A, Dalton J, Ranum L. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. *Neurology* (2003) 60:657-664.
29. Muley SA, **Day JW**. Autoimmune Rippling Muscle. *Neurology* (2003) 61:869–870.
30. Walk D, Li LYJ, Parry GJP, **Day JW**. Rapid Resolution of Quadriplegic CIDP by Combined Plasmapheresis and IVIg. *Neurology* (2004) 62 155-156.
31. Liquori CL, Ikeda Y, Weatherspoon M, Ricker K, Schoser BGH, Dalton JC, **Day JW**, Ranum LPW. Myotonic Dystrophy Type 2: Human Founder Haplotype and Evolutionary Conservation of the Repeat Tract. *Am J Hum Genet* (2003) 73:849-862.
32. Savkur RS, Philips AV, Cooper TA, Dalton JC, Moseley ML, Ranum LP, **Day, JW**. Insulin receptor splicing alternation in myotonic dystrophy type 2. *Am J Hum Genet* (2004) 74(6):1309-13.
33. Schoser BG, Ricker K, Schneider-Gold C, Hengstenberg C, Durre J, Bultmann B, Kress W, **Day JW**, Ranum LP. Sudden cardiac death in myotonic dystrophy type 2. *Neurology* (2004) 63(12):2402-4.
34. Ikeda Y., Dalton JC, Moseley ML, Gardner KL, Bird TD, Ashizawa T, Seltzer WK, Pandolfo M, Milunsky A, Potter NT, Shoji M, Vincent JB, **Day JW**, Ranum, LPW. Spinocerebellar ataxia type 8: molecular genetic comparisons and haplotype analysis of 37 ataxia families. *Am J Hum Genet.* (2004) 75:3-16.
35. Meisler MH, Trudeau MM, Dalton JC, **Day JW**, Ranum LP. Gene symbol: SCN8A. Disease: Ataxia. Accession #Hd0520. *Hum Genet* (2006) 118(6):776.
36. Trudeau MM, Dalton JC, **Day JW**, Ranum LP, Meisler MH. Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation. *J Med Genet* (2006) 43(6):527-30.
37. Margolis JM, Schoser BG, Moseley ML, **Day JW**, Ranum LP. DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. *Hum Mol Genet* (2006) 15(11):1808-15.
38. Ikeda Y, Dick KA, Weatherspoon MR, Gincel D, Armbrust KR, Dalton JC, Stevanin G, Durr A, Zuhlke C, Burk K, Clark HB, Brice A, Rothstein JD, Schut LJ, **Day JW**, Ranum LPW. Spectrin mutations cause spinocerebellar ataxia type 5. *Nature Genet* (2006) 38: 184-190.
39. Moseley ML, Zu T, Ikeda Y, Gao W, Mosemiller AK, Daughters RS, Chen G, Weatherspoon MR, Clark HB, Ebner TJ, **Day JW**, Ranum LPW. Transgenic mouse model helps define the molecular pathophysiology of spinocerebellar ataxia type 8. *Nature Genet* (2006) 38:758-69.
40. Meisler MH, Trudeau MM, Dalton JC, **Day JW**, Ranum LP. Gene symbol: SCN8A. Disease: Ataxia. Accession #Hd0520. (2006) 118(6):776.
41. Saito T, Amakusa Y, Kimura T, Yahara O, Aizawa H, Ikeda Y, **Day JW**, Ranum LP, Ohno K, Matsuura T. Myotonic dystrophy type 2 in Japan: ancestral origin distinct from Caucasian families. *Neurogenetics* (2008) 9(1):61-3.
42. **Day, JW**. Congenital muscular dystrophy in a new age. *Neurology* (2008) 71(5): 308-9.

43. Krueger KAD, Tsuji S, Fukuda Y, Takahashi Y, Goto J, Dalton JC, Miller MB, **Day JW**, Ranum LPW. SNP haplotype mapping in a small ALS family.. *Plos One* (2009) 4(5):e3687.
44. Arikian A, Boutelle K, Peterson CB, Dalton, JC, **Day JW**, Crow SJ. Targeting Parents for the Treatment of Pediatric Obesity in Boys with Duchenne Muscular Dystrophy. *Eat Weight Disord* (2010) 15(3):161-5. PMID: 21150251
45. Karachunski PI, Margolis J, Dehnbostel J, Dalton JC, Ranum LPW, **Day JW**. Potassium Channelopathy Causes Familial Neuromyotonia with Delayed and Prolonged Trousseau Response. (in preparation).
46. Karachunski PI, Margolis M, Dalton JC, **Day JW**. Fluctuating LGMD-2I in Twin Brothers: Response to Prednisone. (submitted).
47. Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Gappmaier E, Howard MT, Sampson JB, Mendell JR, Wall C, King WM, Pestronk A, Florence JM, Connolly AM, Mathews KD, Stephan CM, Laubenthal KS, Wong BL, Morehart PJ, Meyer A, Finkel RS, Bonnemann CG, Medne L, **Day JW**, Dalton JC, Margolis MK, Hinton VJ; United Dystrophinopathy Project Consortium, Weiss RB. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. *Hum Mutat* (2009) 30(12):1657-66. PMID: 19937601
48. de Greef JC, Lemmers RJLF, Camano P, **Day JW**, Desnuelle C, DunandM, van Engelen BGM, Kiuri-Enari S, Padberg GW, Rosa AL, Sacconi S, Spuler S, Tarnopolsky M, Venance SL, Frants RR, van der Maarel SM, Tawil R. D4Z4 repeat contraction-independent facioscapulohumeral muscular dystrophy type 2 represents a true FSHD subgroup. *Neurology* (2010) 75(17):1548-54. PMID: 20975055
49. Appel SH, Cwik VA, **Day JW**. Trauma, TDP-43, and amyotrophic lateral sclerosis. *Muscle Nerve* (2010) 42(6):851-2. PMID: 21104858
50. Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Howard MT, Sampson JB, Swoboda KJ, Bromberg MB, Mendell JR, Taylor L, Anderson CB, Pestronk A, Florence J, Connolly AM, Mathews KD, Wong B, Finkel RS, Bonnemann CG, **Day JW**, McDonald C, Weiss RB. Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. *Hum Mutat* (2011) 32:299–308. PMID: 21972111
51. Wozniak JR, Mueller BA, Ward EE, Lim KO, **Day JW**. White matter abnormalities and neurocognitive correlates in children and adolescents with myotonic dystrophy type 1: a diffusion tensor imaging study. *Neuromuscul Disord* (2011) 21(2):89-96. PMID: 21169018
52. Rau F, Freyermuth F, Fugier C, Fischer MC, Jost B, Gourdon G, Duboc D, **Day JW**, Wahbi K, Fujimura H, Takahashi MP, Dreumont N, Furling D, Charlet N. Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. *Nat Struct Mol Biol.* (2011) 8:840-5. PMID: 21685920
53. Escolar DM, Hache LP, Clemens PR, Cnaan A, McDonald CM, Viswanathan V, Kornberg AJ, Bertorini TE, Nevo Y, Lotze T, Pestronk A, Ryan MM, Monasterio E, **Day JW**, Zimmerman A, Arrieta A, Henricson E, Mayhew J, Florence J, Hu F, Connolly AM. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. *Neurology.* 2011 Aug 2;77(5):444-52. PMID: 21753160

54. Flanigan KM, Ceco E, Lamar KM, Kaminoh Y, Dunn DM, Mendell JR, King WM, Pestronk A, Florence JM, Mathews KD, Finkel RS, Swoboda KJ, Gappmaier E, Howard MT, **Day JW**, McDonald C, McNally EM, Weiss RB; United Dystrophinopathy Project. LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy. *Ann Neurol.* (2012). PMID: 23440719
55. Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Howard MT, Sampson JB, Swoboda KJ, Bromberg MB, Mendell JR, Taylor LE, Anderson CB, Pestronk A, Florence JM, Connolly AM, Mathews KD, Wong B, Finkel RS, Bonnemann CG, **Day JW**, McDonald C; United Dystrophinopathy Project Consortium, Weiss RB. Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. *Hum Mutat.* 2011 Mar;32(3):299-308. PMID:21972111
56. Franc DT, Muetzel RL, Robinson PR, Rodriguez CP, Dalton JC, Naughton CE, Mueller BA, Wozniak JR, Lim KO, **Day JW**. Cerebral and muscle MRI abnormalities in myotonic dystrophy. *Neuromuscul Disord.* 2012 Jun;22(6):483-91. PMID: 22290140
57. Blonsky K, Monckton D, Wieringa B, Schoser B, **Day JW**, Engelen Bv.2010 Marigold therapeutic strategies for myotonic dystrophy. *Neuromuscul Disord.* (2012) 22(1):87-94. PMID: 21852134
58. Hilbert JE, Kissel JT, Luebbe EA, Martens WB, McDermott MP, Sanders DB, Tawil R, Thornton CA, Moxley RT 3rd; Registry Scientific Advisory Committee. If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). *Contemp Clin Trials.* 2012;33(2):302-11. PMID: 22155025
59. Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, Salajegheh MK, Venance SL, Cifaloni E, Matthews E, Meola G, Herbelin L, Griggs RC, Barohn RJ, Hanna MG; Consortium for Clinical Investigation of Neurologic Channelopathies. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. *JAMA.* 2012 Oct 3;308(13):1357-65. PMID: 23032552
60. Wozniak JR, Mueller BA, Bell CJ, Muetzel RL, Lim KO, **Day JW**. Diffusion tensor imaging reveals widespread white matter abnormalities in children and adolescents with myotonic dystrophy type 1. *J Neurol.* (2013) 260:1122-31. PMID: 23192171
61. Hartweck LM, Anderson LJ, Lemmers RJ, Dandapat A, Toso EA, Dalton JC, Tawil R, **Day JW**, van der Maarel SM, Kyba M. A focal domain of extreme demethylation within D4Z4 in FSHD2. *Neurology.* (2013)80:392-9. PMID: 23284062
62. McDonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, Glanzman AM; PTC124-GD-007-DMD Study Group, Spiegel R, Barth J, Elfring G, Reha A, Peltz S. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. *Muscle Nerve.* (2013) 48(3):343-56. PMID:23681930
63. McDonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, Glanzman AM; PTC124-GD-007-DMD Study Group, Spiegel R, Barth J, Elfring G, Reha A, Peltz SW. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. *Muscle Nerve.* (2013) 48(3):357-68. PMID: 23674289

64. Connolly AM, Florence JM, Cradock MM, Malkus EC, Schierbecker JR, Siener CA, Wulf CO, Anand P, Golumbek PT, Zaidman CM, Philip Miller J, Lowes LP, Alfano LN, Viollet-Callendret L, Flanigan KM, Mendell JR, McDonald CM, Goude E, Johnson L, Nicorici A, Karachunski PI, **Day JW**, Dalton JC, Farber JM, Buser KK, Darras BT, Kang PB, Riley SO, Shriber E, Parad R, Bushby K, Eagle M; MDA DMD Clinical Research Network. Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. *Neuromuscul Disord* (2013) 23(7):529-39. PMID: 23726376
65. Mourkioti F, Kustan J, Kraft P, **Day JW**, Zhao MM, Kost-Alimova M, Protopopov A, Depinho RA, Bernstein D, Meeker AK, Blau HM. Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy. *Nat Cell Biol.* (2013) 15(8):895-904. PMID: 23831727.
66. Hilbert JE, Ashizawa T, **Day JW**, Luebke EA, Martens WB, McDermott MP, Tawil R, Thornton CA, Moxley RT 3rd. Diagnostic odyssey of patients with myotonic dystrophy. *J Neurol.* (2013) 260(10):2497-504. PMID: 23807151
67. Mourkioti F, Kustan J, Kraft P, **Day JW**, Zhao MM, Kost-Alimova M, Protopopov A, DePinho RA, Bernstein D, Meeker AK, Blau HM. Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy. *Nat Cell Biol.* 2013 Aug;15(8):895-904. PMID: 23831727
68. Couthouis J, Raphael AR, Siskind C, Findlay AR, Buenrostro JD, Greenleaf WJ, Vogel H, **Day JW**, Flanigan KM, Gitler AD. Exome sequencing identifies a DNAJB6 mutation in a family with dominantly-inherited limb-girdle muscular dystrophy. *Neuromuscul Disord.* 2014 May;24(5):431-5. PMID:24594375
69. Wozniak JR, Mueller BA, Lim KO, Hemmy LS, **Day JW**. Tractography reveals diffuse white matter abnormalities in Myotonic Dystrophy Type 1. *J Neurol Sci.* 2014 Jun 15;341(1-2):73-8. PMID: 24768314
70. Raphael AR, Couthouis J, Sakamuri S, Siskind C, Vogel H, **Day JW**, Gitler AD. Congenital muscular dystrophy and generalized epilepsy caused by GMPPB mutations. *Brain Res.* 2014 Aug 5;1575:66-71. PMID:24780531
71. Connolly AM, Florence JM, Cradock MM, Eagle M, Flanigan KM, McDonald CM, Karachunski PI, Darras BT, Bushby K, Malkus EC, Golumbek PT, Zaidman CM, Miller JP, Mendell JR; MDA DMD Clinical Research Network. One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development. *Pediatr Neurol.* 2014 Jun;50(6):557-63.. PMID: 24842254
72. Connolly AM, Malkus EC, Mendell JR, Flanigan KM, Miller JP, Schierbecker JR, Siener CA, Golumbek PT, Zaidman CM, McDonald CM, Johnson L, Nicorici A, Karachunski PI, **Day JW**, Kelecic JM, Lowes LP, Alfano LN, Darras BT, Kang PB, Quigley J, Pasternak AE, Florence JM; and MDA DMD Clinical Research Network. Outcome reliability in non ambulatory boys/men with duchenne muscular dystrophy. *Muscle Nerve.* 2014 Jul 24. PMID: 25056178
73. Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, Connolly AM, **Day JW**, Flanigan KM, Goemans N, Jones KJ, Mercuri E, Quinlivan R, Renfroe JB, Russman B, Ryan MM, Tulinius M, Voit T, Moore SA, Lee Sweeney H, Abresch RT, Coleman KL, Eagle M, Florence J, Gappmaier E, Glanzman AM, Henricson E, Barth J, Elfring GL, Reha A, Spiegel RJ, O'donnell MW, Peltz SW,

Mcdonald CM; PTC124-GD-007-DMD STUDY GROUP. Ataluren treatment of patients with nonsense mutation dystrophinopathy. *Muscle Nerve*. 2014 Oct;50(4):477-87. PMID: 25042182

ABSTRACTS:

1. Aljure E, **Day JW**, Bennett MVL. Implied locus of habituation of the Mauthner fiber mediated startle reflex in the hatchetfish. Soc Neurosci Abstr 5:735, 1979.
2. Huse WD, **Day JW**, Bennett MVL. Voltage dependence of synaptic currents at a CNS synapse in the hatchetfish. Soc Neurosci Abstr 5:742, 1979.
3. Hall DH, **Day JW**, Hall LM, Bennett MVL. Alpha-bungarotoxin labeling of an identified central synapse. Soc Neurosci Abstr 7:703, 1981.
4. **Day JW**, Huse WD, Bennett MVL. Two phase decay of MPSPs at the hatchetfish giant synapse. Soc Neurosci Abstr 7:724, 1981.
5. Bennett MVL, **Day JW**. Mauthner fiber reflex: descending activity mediates "habituation" of the response to Mauthner fiber stimulation. Soc Neurosci Abstr (1981) 7:843.
6. **Day JW**, Raskin NH. Sentinel headache without subarachnoid hemorrhage. Neurology 35(suppl 1):268, 1985.
7. **Day JW**. Effect of opiates on the action potential of neuroblastoma cells. Soc Neurosci Abstr 13:769, 1987.
8. Midani H, Parry GJ, **Day JW**. A Case of Inflammatory Neuropathy Misdiagnosed as Charcot-Marie-Tooth. AAEM Annual Meeting, New Orleans, 1993.
9. **Day JW**, Sakamoto C, Lehmann-Horn F, Parry GJ, Iazzo PA. Assessment of dorsiflexor torque to aid in the diagnosis of periodic paralysis. International Congress on Neuromuscular Diseases, Kyoto, 1994, Muscle Nerve Suppl 1:S209, 1994.
10. Bhattacharyya B, **Day JW**, Gomez CM. Transgenic mice with slow acetylcholine receptor ion channels: reduced miniature endplate current amplitudes may be due to desensitization. Soc Neurosci Abstr 20:713, 1994.
11. **Day JW**, Maselli R, Bhattacharyya B, Gomez CM. Acetylcholine receptor mutations alter electrophysiological function in transgenic mice. Neurology 45 (suppl 4): A283, 1995.
12. Brass TJ, **Day JW**, Iazzo PA. Stimulated force measurements in neuromuscular diseases. American Academy of Neurology 45:120P, 1995
13. Wrubel B, **Day JW**, Parry GJ. Needle versus surface electrode recording of sensory nerve action potentials. American Academy of Electrodiagnostic Medicine Annual Meeting, Montreal, 1995
14. Gomez CM, Maselli R, **Day JW**, Wollman RW. Calcium overload and postsynaptic vacuolization in transgenic mice as a function of cholinergic receptor ion channel kinetics. Society for Neuroscience Abstracts 21:1490, 1995.
15. Ranum LPW, Benzow KA, Lundgren JK, Koob MD, **Day JW**. A CTG repeat expansion detected by RED in a five generation kindred with a novel form of myotonic dystrophy. Am J Hum Genet, Suppl A: 280., 1996.
16. **Day JW**, Williams JM, Charnet P, Gomez CM. Slow-channel transgenic mice: a model of transsynaptic calcium overload. Soc for Neuroscience Abstracts 23:1134, 1997.
17. **Day JW**, Leroy B, Pech I, Benzow KA, Ranum LPW. Clinical and Physiological Features of a Novel Form of Myotonic Dystrophy. IX Intl. Conf Neuromuscular Disease, Adelaide, 1998.
18. Ranum LPW, Rasmussen PF, Benzow KA, Koob MD, **Day JW**. Genetic characterization of a novel form of myotonic dystrophy. Amer Soc Human Gen, Denver, 1998.
19. Koob MD, Moseley ML, Schut LJ, Bird TD, Benzow KA, **Day JW**, Ranum LPW. A 3' untranslated CTG repeat causes spinocerebellar ataxia type 8 (SCA8). Amer Soc Human Gen, Denver, 1998.
20. Ranum LPW, Rasmussen PF, Benzow KA, Koob MD, **Day JW**. Genetic mapping and clinical characterization of a second form of myotonic dystrophy (DM2). Amer Soc Human Gen, Denver, 1998.

21. Moseley ML, **Day JW**, Schut LJ, Bird TD, Benzow KA, Koob MD, Ranum LPW. Frequency and dramatic instability of the 3'untranslated CTG repeat causing spinocerebellar ataxia type 8 (SCA8). *Amer Soc Human Gen*, Denver, 1998.
22. Wolfe GI, Barohn RJ, Foster BM, Jackson CB, Kissel JT, **Day JW**, Thornton CA. Intravenous immunoglobulin therapy for generalized myasthenia gravis. *Amer Acad Neur*, Toronto, 1999
23. **Day JW**, Ricker K, Liquori CL, Durand AC, Ranum LPW. The genetic locus for myotonic dystrophy type 2 (*DM2*) also underlies many cases of PROMM. Second International Myotonic Dystrophy Consortium (IDMC) Conference, Research Triangle Park, North Carolina, 1999.
24. Stelow E, Eastlund DT, **Day JW**. Parvovirus infection following plasma exchange using solvent-detergent treated pooled plasma containing parvovirus. *AABB*, 1999
25. Ranum LPW, Moseley ML, Leppert MF, van den Engh G, La Spada AR, Koob MD, **Day JW**. Spinocerebellar ataxia type 8: Massive expansions and deletions may cause reduced penetrance. *Amer Soc Human Gen*, San Francisco, 1999.
26. Koc ON, **Day JW**, Brown D, Andrews P, Peters C, Nieder M, Gerson SL, Lazarus HM, Caplan AI, Laughlin MJ, Raghavan S, Kolodny EH, Krivit W. Results of a phase I clinical trial of allogeneic mesenchymal stem cell (MSC) transplantation in patients with Hurler disease and metachromatic leukodystrophy (MLD). *American Society of Hematology*, 2000.
27. Moseley M, Jacobsen J, Liquori C, Durand A, Davis L, Ikeda Y, Bird T, Spiegel R, Ashizawa T, Pandolfo M, Potter N, Schaefer F, Milunski A, Kennedy J, Seltzer W, Atwood L, Vincent J, **Day JW**, Ranum LPW. SCA8 CTG expansion: evidence for a common haplotype and highly mutable region on both ataxia and non-ataxia chromosomes. *Amer Soc Human Gen*, Philadelphia, 2000.
28. Li L, Walk D, **Day JW**. Rapid Response to Combined Plasma Exchange Followed Immediately by Intravenous Immunoglobulin in Refractory CIDP. *Peripheral Nerve Society*, Innsbruck. 2001.
29. Ranum LPW, Liquori CL, Moseley ML, Jacobsen JF, Phillips A, Savkur R, Kress W, Naylor SL, Cooper T, Ricker K, **Day JW**. Myotonic Dystrophy Type 2 is caused by a CCTG expansion in intron 1 of *ZNF9*. *World Muscle Society*, Salt Lake City, 2001.
30. Ranum LPW, Liquori CL, Moseley ML, Jacobsen JF, Phillips A, Savkur R, Kress W, Naylor SL, Cooper T, Ricker K, **Day JW**. Myotonic Dystrophy Type 2 is caused by a CCTG expansion in intron 1 of *ZNF9*. 3rd International Myotonic Dystrophy Consortium, Kyoto, 2001.
31. **Day JW**, Ricker K, Dick KA, Rasmussen L, Dalton JC, Jacobsen JF, Liquori CL, Kress W, Schneider C, Moseley ML, Ranum LPW. Clinical and Molecular Correlations in Myotonic Dystrophy Type 2. 3rd International Myotonic Dystrophy Consortium, Kyoto, 2001.
32. Ranum LPW, Liquori CL, Moseley ML, Jacobsen JF, Phillips A, Savkur R, Kress W, Naylor SL, Cooper T, Ricker K, **Day JW**. Myotonic Dystrophy Type 2 is caused by a CCTG expansion in intron 1 of *ZNF9*. *Amer Soc Human Gen*, San Diego, *Am J Human Genetics*, 69:211, 2001.
33. Liquori CL, **Day JW**, Ranum LPW. Conserved haplotypes indicate founder mutation in myotonic dystrophy type 2. *Amer Soc Human Gen*, San Diego, 2001, *Am J Human Genetics*, 69:424, 2001.
34. Moseley ML, **Day JW**, Ranum LPW. SCA8 CTG expansion: evidence for a common haplotype and highly mutable region on both ataxia and non-ataxia. *Amer Soc Human Gen*, San Diego, *Am J Human Genetics*, 69:559, 2001.
35. **Day JW**, Wick MJ, Malikowski JM, Dalton JC, Rasmussen L, Ranum LPW. Familial Neuromyotonia: A Distinct Phenotype Due to a Novel Mutation in the Potassium Channel Gene *KCNA1*. *AAN*, Denver, *Neurology* 58:A225, 2002.
36. **Day JW**, Ricker K, Dick KA, Rasmussen L, Dalton JC, Jacobsen JF, Liquori CL, Kress W, Schneider C, Moseley ML, Ranum LPW. Clinical and Molecular Correlations in Myotonic Dystrophy Type 2. *AAN*, Denver, *Neurology* 58:A226, 2002.

37. Ranum LPW, Moseley ML, Jacobsen JF, Liquori CL, Ikeda Y, Bird TD, Ashizawa T, Seltzer W, Vincent J, **Day JW**. The SCA8 CTG Expansion Causes Ataxia: Evidence from Haplotype Analysis. AAN, Denver, Neurology 58:A310, 2002.
38. Ranum LPW, Liquori CL, Moseley ML, Jacobsen JF, Phillips A, Savkur R, Cooper T, Kress W, Ricker K, **Day JW**. Expanding Role of RNA Pathogenesis: Molecular genetics of DM2 clarify pathogenic mechanism of myotonic dystrophy. AAN, Denver, Neurology 58:A317, 2002.
39. **Day JW**, Liu H, Dalton J, Ikeda Y, Ranum LPW. MRI in SCA8: dramatic cerebellar atrophy in clinically unaffected gene carriers explains some of the reduced penetrance. Amer Soc Human Gen, Los Angeles, 2003.
40. Moseley ML, Weatherspoon M, Jin D, Clark HB, **Day JW**, Ranum LPW. SCA8 BAC Transgenic mice: Pathogenic CTG expansion and expression models. Amer Soc Human Gen, Los Angeles, 2003.
41. Malikowski JM, Moseley ML, Mosemiller AK, Jin D, Ricker K, Schoser B, Kress W, **Day JW**, Ranum LPW. The myotonic dystrophy type 2 (DM2) CCTG expansion does not prevent allele specific ZNF9 expression. Amer Soc Human Gen, Los Angeles, 2003.
42. Ikeda Y, Liquori CL, Weatherspoon M, Ricker K, Schoser BGH, Dalton JC, **Day JW**, Ranum LPW. Myotonic Dystrophy Type 2: Human Founder Haplotype and Evolutionary Conservation of the Repeat Tract. Amer Soc Human Gen, Los Angeles, 2003.
43. Moseley ML, Weatherspoon M, Jin D, **Day JW**, Ranum LPW. SCA8 BAC Transgenic mice have a progressive and often lethal neurological phenotype demonstrating pathogenicity of the CTG expansion. Soc for Neuroscience, New Orleans, 2003.
44. **Day JW**, Dalton J, Liu H, Ranum LPW. Reduced Penetrance of Spinocerebellar Ataxia type 8 is Partly Explained by Volumetric MRI of Cerebellum. Amer Acad Neurology, San Francisco, 2004.
45. Ranum LPW, **Day JW**. Myotonic dystrophy: RNA pathogenesis comes into focus. Am. J. Hum. Genet. 74:793-804, 2004.
46. Update on the Pathophysiology of the Myotonic Dystrophies, World Muscle Society Keynote Address, Goteborg, Sweden, September, 2004
47. Ranum LPW, Dick KA, Weatherspoon MR, Dalton JC, Stevanin G, Durr A, Zuehlke C, Buerk K, Brice A, Clark BH, Schut LJ, **Day JW**, Ikeda Y. Spectrin mutations cause Spinocerebellar Ataxia Type 5. Soc Neurosci, Washington D.C., 2005.
48. Dick K, Dalton JC, Miller M, **Day JW**, Ranum LPW. Back to genetics: increasing the power of tiny families for linkage analysis using haploid cell lines. Amer Soc Human Gen, Salt Lake City, 2005.
49. Ranum LPW, Dick KA, Weatherspoon MR, Dalton JC, Stevanin G, Durr A, Zuehlke C, Buerk K, Brice A, Clark BH, Schut LJ, **Day JW**, Ikeda Y. Spectrin mutations cause SCA5. Amer Soc Human Gen, Salt Lake City, 2005.
50. **Day JW**. Myotonic dystrophy Clinical Features. Invited Symposium Presentation. International Neuromuscular Congress, Istanbul, 2006.
51. **Day JW**. RNA pathogenesis of Neuromuscular Disease. Invited Plenary Session Presentation. International Neuromuscular Congress, Istanbul, 2006.
52. **Day JW**. Potassium channel mutations responsible for familial neuromyotonia. International Non-Dystrophic Myotonias Conference, Kansas University, 2008
53. Karachunski PI, Margolis M, Dalton JC, **Day JW**. LGMD 2I in Twin Brothers: Response to Prednisone. American Academy of Neurology, Seattle, 2009
54. Lim KO, Franc D, Mueller B, **Day JW**. CNS Diffusion Tensor Imaging in Adults with DM1 and DM2. International Myotonic Dystrophy Consortium, Wurzburg, 2009
55. Jeffrey R. Wozniak, Bryon Mueller, Erin E. Ward, Kelvin O. Lim, & **Day JW**. Neuropsychological and DTI results in adolescents with DM1. International Myotonic Dystrophy Consortium, Wurzburg, 2009

56. Lim KO, Franc D, Mueller B, **Day JW**. CNS Diffusion Tensor Imaging in Adults with DM1 and DM2. International Myotonic Dystrophy Consortium, Wurzberg, 2009
57. Jeffrey R. Wozniak, Bryon Mueller, Erin E. Ward, Kelvin O. Lim, & **Day JW**. Neuropsychological and DTI results in adolescents with DM1. International Myotonic Dystrophy Consortium, Wurzberg, 2009
58. Jeffrey R. Wozniak, Bryon Mueller, Erin E. Ward, Kelvin O. Lim, & **Day JW**. Structural and functional CNS deficits in Myotonic Dystrophy Adolescents. International Myotonic Dystrophy Consortium, Clearwater, FL, 2011
59. **Day JW**. Gastrointestinal effects of Myotonic Dystrophy. International Myotonic Dystrophy Consortium, Clearwater, FL, 2011
60. **Day JW**. Effects of Myotonic Dystrophy on Sleep and Psychological Functioning. International Myotonic Dystrophy Consortium, Clearwater, FL, 2011
61. Sakamuri S, Gitler A, **Day JW**. A Novel Form of Severe Infantile Nemaline Myopathy caused by an in-frame deletion in TNNT1. American Academy of Neurology Ann Mtg, Philadelphia, PA, 2014

BOOK CHAPTERS AND REVIEW ARTICLES:

1. **Day JW**. Neurology Section on Headache and Pain. Medical Knowledge Self-Assessment Program, American College of Physicians, 1991.
2. Iaizzo PA, Day JW. The potential for anesthetic complications in patients with a muscle disorder. *Progress in Anesthesiology*, volume 10, chapter 9, pages 151-172, 1996.
3. Schut, LJ, **Day JW**, Clark HB, Koob MD, and Ranum LPW. Spinocerebellar ataxia type 5 (SCA5) in Neurological Ataxia. ed. T. Klockgether, pp. 435-445, 2000.
4. Dalton J, **Day JW**, Ranum LPW. In: GeneReviews: Genetic Disease Online Reviews at GeneTests-GeneClinics [database online]. Copyright, University of Washington, Seattle. Available at <http://www.geneclinics.org>, 2001.
5. Liquori, CL, Schut LJ, Clark HB, **Day JW**, Ranum LPW. Spinocerebellar ataxia type 5 (SCA5). in *Cerebellar Ataxias* ed. M. Pandolfo, Cambridge University Press pp 445-450, 2001.
6. Moseley ML, Schut LJ, **Day JW**, Ranum LPW. Spinocerebellar ataxia type 8 (SCA8). in *Cerebellar Ataxias* ed. M. Pandolfo, Cambridge University Press pp 469-480, 2001.
7. **Day JW** and Ranum LPW. Myotonic Dystrophies. in *Neuromuscular Disorders in Clinical Practice*. ed. by B. Katirji, H.J. Kaminski, D.C. Preston, R.L. Ruff and B.E. Shapiro. Butterworth Heinemann, Boston, pp1078-1091, 2002.
8. Ranum LP, **Day JW**. Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2. *Curr Neurol Neurosci Rep*. 2(5):465-70, 2002.
9. Ranum, LPW, **Day JW**. Dominant non-coding microsatellite expansion disorders. *Current Opinions in Genetics and Development* 12:266-271, 2002.
10. Ranum, LPW, Dick KA, **Day JW**. Spinocerebellar ataxia type 5. (SCA5) in *Genetics of Movement Disorders* ed. Stefan Pulst. Academic Press, 2002.
11. Mosemiller AK, Dalton JC, **Day JW**, Ranum LP. Molecular genetics of spinocerebellar ataxia type 8 (SCA8). *Cytogenetic & Genome Research*. 100(1-4):175-83, 2003.
12. Ranum, L. P. W. and **J. W. Day**. Myotonic dystrophy: RNA pathogenesis comes into focus. *Am. J. Hum. Genet.* 74:793-804, 2004.
13. Ranum, L. P. W. and **J. W. Day** (2004). Pathogenic RNA repeats and their expanding role in genetic disease. *Trends in Genetics* 20(10):506-12, 2004.
14. Ranum LP, **Day JW**. Myotonic dystrophy: RNA pathogenesis comes into focus. *Am. J. Hum. Genet.* 74:793-804, 2004.

15. **Day JW**, Ranum, LPW. RNA Pathogenesis of the Myotonic Dystrophies. *Neuromuscul. Disord.* 15(1):5-16, 2005.
16. **Day JW**, Ranum, LPW. Genetics and Molecular Pathogenesis of the Myotonic Dystrophies. *Curr Neurol Neurosci Rep.* 2005 Feb;5(1):55-9 2005.
17. Dick KA, Margolis JM, **Day JW**, Ranum LP. Dominant non-coding repeat expansions in human disease. *Genome Dyn* 1:67-83, 2006.
18. Dalton JC, Ranum LPW, **Day JW** (September 2006) Myotonic Dystrophy Type 2 in: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997-2007. Available at <http://www.genetests.org>. PMID: 20301639
19. **Day JW**, Thornton C. The Myotonic Dystrophies. *Disorders of Voluntary Muscle*, ed Karpati G, Griggs R, Bushby K, 2009.
20. Karachunski PI, **Day, JW**. Myotonic Muscular Dystrophy. *Current Opinions in Neurology*, 2009.
21. Ikeda Y, Ranum LP, **Day JW**. Clinical and genetic features of spinocerebellar ataxia type 8. *Handb Clin Neurol.* 2012;103:493-505. PMID: 21827909
22. Dick KA, Ikeda Y, **Day JW**, Ranum LP. Spinocerebellar ataxia type 5. *Handb Clin Neurol.* 2012;103:451-9. PMID: 21827906
23. Dalton JC, Ranum LPW, **Day JW**. Myotonic Dystrophy Type 2. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle (2013)